These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 21868512

  • 21. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001.
    Wedel S, Hudak L, Seibel JM, Juengel E, Tsaur I, Wiesner C, Haferkamp A, Blaheta RA.
    Life Sci; 2011 Feb 28; 88(9-10):418-24. PubMed ID: 21192952
    [Abstract] [Full Text] [Related]

  • 22. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells.
    Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F.
    Clin Cancer Res; 2004 Oct 15; 10(20):7031-42. PubMed ID: 15501983
    [Abstract] [Full Text] [Related]

  • 23. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK, Li ZH, Han XQ, Yi JH, Wang ZH, Hou JL, Feng CR, Fang QH, Wang HH, Zhang PF, Wang FS, Shen J, Wang P.
    Cancer Chemother Pharmacol; 2010 Nov 15; 66(6):1131-40. PubMed ID: 20838997
    [Abstract] [Full Text] [Related]

  • 24. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
    Aissat N, Le Tourneau C, Ghoul A, Serova M, Bieche I, Lokiec F, Raymond E, Faivre S.
    Cancer Chemother Pharmacol; 2008 Jul 15; 62(2):305-13. PubMed ID: 17912526
    [Abstract] [Full Text] [Related]

  • 25. mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma.
    Schedel F, Pries R, Thode B, Wollmann B, Wulff S, Jocham D, Wollenberg B, Kausch I.
    Oncol Rep; 2011 Mar 15; 25(3):763-8. PubMed ID: 21240463
    [Abstract] [Full Text] [Related]

  • 26. The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells.
    Zitzmann K, De Toni EN, Brand S, Göke B, Meinecke J, Spöttl G, Meyer HH, Auernhammer CJ.
    Neuroendocrinology; 2007 Mar 15; 85(1):54-60. PubMed ID: 17310129
    [Abstract] [Full Text] [Related]

  • 27. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
    Chang SB, Miron P, Miron A, Iglehart JD.
    J Surg Res; 2007 Mar 15; 138(1):37-44. PubMed ID: 17109887
    [Abstract] [Full Text] [Related]

  • 28. Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland.
    Torres-Arzayus MI, Yuan J, DellaGatta JL, Lane H, Kung AL, Brown M.
    Cancer Res; 2006 Dec 01; 66(23):11381-8. PubMed ID: 17145884
    [Abstract] [Full Text] [Related]

  • 29. Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells.
    Qu Y, Wang J, Sim MS, Liu B, Giuliano A, Barsoum J, Cui X.
    Breast Cancer Res Treat; 2010 Jun 01; 121(2):311-21. PubMed ID: 19609669
    [Abstract] [Full Text] [Related]

  • 30. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.
    Manegold PC, Paringer C, Kulka U, Krimmel K, Eichhorn ME, Wilkowski R, Jauch KW, Guba M, Bruns CJ.
    Clin Cancer Res; 2008 Feb 01; 14(3):892-900. PubMed ID: 18245553
    [Abstract] [Full Text] [Related]

  • 31. Enhanced radiation damage of tumor vasculature by mTOR inhibitors.
    Shinohara ET, Cao C, Niermann K, Mu Y, Zeng F, Hallahan DE, Lu B.
    Oncogene; 2005 Aug 18; 24(35):5414-22. PubMed ID: 15940265
    [Abstract] [Full Text] [Related]

  • 32. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I.
    Endocr Relat Cancer; 2009 Sep 18; 16(3):1017-27. PubMed ID: 19509067
    [Abstract] [Full Text] [Related]

  • 33. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
    Grozinsky-Glasberg S, Rubinfeld H, Nordenberg Y, Gorshtein A, Praiss M, Kendler E, Feinmesser R, Grossman AB, Shimon I.
    Mol Cell Endocrinol; 2010 Feb 05; 315(1-2):87-94. PubMed ID: 19815051
    [Abstract] [Full Text] [Related]

  • 34. P53-mediated cell cycle arrest and apoptosis through a caspase-3- independent, but caspase-9-dependent pathway in oridonin-treated MCF-7 human breast cancer cells.
    Cui Q, Yu JH, Wu JN, Tashiro S, Onodera S, Minami M, Ikejima T.
    Acta Pharmacol Sin; 2007 Jul 05; 28(7):1057-66. PubMed ID: 17588343
    [Abstract] [Full Text] [Related]

  • 35. Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro.
    Yerushalmi R, Nordenberg J, Beery E, Uziel O, Lahav M, Luria D, Fenig E.
    Exp Oncol; 2007 Jun 05; 29(2):126-31. PubMed ID: 17704745
    [Abstract] [Full Text] [Related]

  • 36. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
    McGuire KP, Ngoubilly N, Neavyn M, Lanza-Jacoby S.
    J Surg Res; 2006 May 15; 132(2):208-13. PubMed ID: 16580691
    [Abstract] [Full Text] [Related]

  • 37. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.
    Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF, Testa JR.
    Clin Cancer Res; 2007 Jul 15; 13(14):4261-70. PubMed ID: 17634556
    [Abstract] [Full Text] [Related]

  • 38. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2010 Jan 15; 51(1):421-9. PubMed ID: 19661225
    [Abstract] [Full Text] [Related]

  • 39. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
    Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G, Milella M.
    Cancer Res; 2006 Jun 01; 66(11):5549-54. PubMed ID: 16740688
    [Abstract] [Full Text] [Related]

  • 40. The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells.
    Zheng J, Zou X, Yao J.
    Chemotherapy; 2012 Jun 01; 58(4):273-81. PubMed ID: 23006739
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.